Patent ID: 11903955
Assignee: ASTRAZENECA, AB
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 12:
13. The method of claim 1, wherein the method satisfies at least one of the following conditions:
a) the method numerically reduces that absolute risk of the composite endpoint of hospitalization for HF, cardiovascular death or urgent HF visit in a patient;
b) the method results in a nominally significant risk reduction of the composite endpoint of hospitalization for HF, cardiovascular death or urgent HF visit in a patient;
c) the method results in a numerical reduction in the composite endpoint events of hospitalization for HF, cardiovascular death or urgent HF visit in a patient;
d) the method results in a numerical reduction in the risk of composite endpoint events of hospitalization for HF, cardiovascular death or urgent HF visit in a patient;
e) the method results in a decrease in mean change of NT-proBNP levels in a patient within 8 months of the start of treatment; and/or
f) the method results in a decrease in mean change of NT-probBNP levels of −278 pg/ml in a patient within 8 months of the start of treatment.